Academic Talk: From Nature to Nano: Bioinspired Intelligent Delivery Systems

time:2024-06-24Hits:10设置

Presenter:Xiaoqi Sun,Icahn School of Medicine at Mount Sinai

Topic:From Nature to Nano: Bioinspired Intelligent Delivery Systems

Time:2:00 PM, June 26th(Wednesday)

Location:909-B

Abstract:

Nature is our most profound teacher. By mimicking biological mechanisms, we can devise intelligent nano delivery systems. In this presentation, I will begin by discussing how to leverage the body's inherent transportation systems, such as red blood cells and high-density lipoproteins, for the efficient delivery of drugs and vaccines. Additionally, I will explore the critical role of nutritional metal ions in immune regulation and demonstrate how these ions can be utilized to modulate immune responses. Using bioinspired metal ion-coordinated lipid nanoparticles, we can not only enhance the delivery of STING agonists but also fine-tune intracellular signaling pathways for superior therapeutic outcomes. Lastly, I will discuss how certain physiological mechanisms can be harnessed to maximize the efficacy of lipid nanoparticles for tissue/cell-specific delivery and in vivo CRISPR gene editing. Overall, bioinspired intelligent delivery systems hold great promise for addressing the current challenges of drug and gene delivery.


Biogaphy

A person wearing glasses and a black shirt with mountains in the background  Description automatically generated

Dr. Xiaoqi Sun is an incoming Assistant Professor in the Department of Immunology and Immunotherapy, the Icahn Genomics Institute (IGI) and the Lipschultz Precision Immunology Institute at Icahn School of Medicine at Mount Sinai. He is currently a Scientist and Delivery Team Leader at Editas Medicine. Before that, he obtained his PhD in Pharmaceutical Sciences from the University of Michigan in 2021 (Advisor: James Moon) and MS in Chemistry from Soochow University in 2016 (Advisor: Zhuang Liu). His research interests focus on interdisciplinary studies across CRISPR gene editing, immune engineering and cell therapy for treatment of severe diseases.He has published 31 peer-reviewed papers and filed 24 patent applications, which laid the foundation of 2 startup companies and 1 drug candidate tested in Phase I clinical trial. His research has been recognized by multiple prestigious awards, including the CRS PhD Thesis Award and the Rackham Pre-doctoral Fellowship.


Contact:Prof. FENG Liangzhu


返回 原图
/